Atlas Trials

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

Clinical trial NCT07385001 · RECRUITING

Trial details

NCT number
NCT07385001
Sponsor
Tang-Du Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell CarcinomaIvonescimabNeoadjuvant
Start date
2026-01-28
Primary completion
2027-01-28
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.